Lupus Nephritis Treatment Consensus and Future Directions
Reviewers discussed new and conventional therapies for lupus nephritis and the prospect of precision medicine.
Reviewers discussed new and conventional therapies for lupus nephritis and the prospect of precision medicine.
A review of scientific papers highlights recent advances in lupus nephritis management.
CABA-201 is a 4-1BB-containing fully human CD19-CAR T cell therapy.
Kidney function remained stable throughout the 25 week treatment period.
More than a third of lupus hospitalizations lacked follow-up with a primary care physician or rheumatologist.
According to investigators, the existing NIH definition of interstitial inflammation in the kidneys of patients with lupus nephritis needs to be modified to account for inflammation in areas with and without fibrosis.
Histologic lesions in the kidney may reflect systemic processes that lead to cardiovascular events, according to investigators.
Serum beta-2 microglobulin can be used to monitor kidney damage in systemic lupus erythematosus for earlier diagnosis of lupus nephritis.
Patients receiving significant amount of immunosuppression prior to kidney transplantation should be counseled on these malignancy risks, according to investigators.
Early diagnosis and treatment of childhood-onset systemic lupus erythematosus is important to prevent lupus nephritis outcomes such as end-stage kidney disease.